FDA approves three new Takeda type 2 diabetes therapies
Takeda expects to launch the type 2 diabetes therapies as adjuncts to diet and exercise in the summer of 2013. Takeda Pharmaceuticals USA president Douglas Cole said, "Takeda
Takeda expects to launch the type 2 diabetes therapies as adjuncts to diet and exercise in the summer of 2013. Takeda Pharmaceuticals USA president Douglas Cole said, "Takeda
The single dose Pneumococcal 13-valent conjugate vaccine [Diphtheria CRM197 Protein] will provide protection from invasive disease caused by 13 Streptococcus pneumoniae serotypes. Pfizer vaccine president Susan Silbermann said,
The CE-marked solution enables clinicians to plan and perform high-dose-rate (HDR) brachytherapy treatments for prostate cancer using real-time ultrasound guidance. The treatment involves delivery of radiotherapy from inside
The commencement of the study trigered a $30m milestone payment to Threshold Pharmaceuticals from Merck under a license and co-development agreement signed between the companies. Randomized, placebo-controlled Phase
In the double-blind study, 845 patients were administered with Folfox or Folfiri and bevacizumab as the front-line treatment of locally-advanced or metastatic colorectal cancer. Neulasta demonstrated the significant
Each of the double-blind Phase 3 trials will randomize 840 HIV-1 infected patients containing a viral load of 1,000 copies/mL or more with a once-daily tablet containing TAF
The partnership aims to develop, improve and embed bioprocesses in order to facilitate the delivery of novel products for Almac’s biocatalysis business. Under the completion of Knowledge Transfer
Eeva test has been designed to improve the vitro fertilization (IVF) outcomes by assessing the viability of the embryo. The test measures various cell-division parameters, which are scientifically
The grant, entitled ‘Circulating Tumor Cell Enumeration Product’, will support the development and clinical validation of assay to detect and characterize circulating tumor cells (CTCs) in lung cancer
Response’s Flu A + B and RSV tests run on the RAMP 200 Reader diagnostic platform, which features multi-port capability to run up to 12 tests per hour